DexTech Medical finalizes clinical study report for myeloma treatment

DexTech Medical has finalized the clinical study report (CSR) for its myeloma treatment research. The documentation provides a formal overview of findings from the study, confirming data previously released by the company.

The completion of this report follows an administrative error on October 27, 2026, which resulted in the initial English-language filing containing Swedish text. The company confirmed that no changes were made to the substantive content of the study findings during the correction process.

Myeloma research remains a competitive area within the pharmaceutical sector, with various stakeholders monitoring the efficacy and safety profiles of potential new therapies. DexTech Medical's documentation marks a transition point in the regulatory and development roadmap for the treatment under investigation.